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Abstract
Background: It is not elucidated that there is treatment-related damage in elderly patients with antineutrophil
cytoplasmic antibody (ANCA)–associated vasculitis (AAV).
Methods: Elderly (≥ 75 years of age) patients were enrolled from two nationwide prospective inception cohort
studies. The primary outcome was 12-month treatment-related Vasculitis Damage Index (VDI) score. Secondary
outcomes included serious infections within 6 months, total VDI score, remission, and relapse. Patient characteristics
and outcomes were compared across three different initial glucocorticoid (GC) dose groups: high-dose,
prednisolone (PSL) ≥ 0.8 mg/kg/day; medium-dose, 0.6 ≤ PSL < 0.8 mg/kg/day; and low-dose, PSL < 0.6 mg/kg/day.
Results: Of the 179 eligible patients, the mean age was 80.0 years; 111 (62%) were female. The mean Birmingham
Vasculitis Activity Score was 16.1. Myeloperoxidase-ANCA findings were positive in 168 (94%) patients, while
proteinase 3-ANCA findings were positive in 11 (6%). The low-dose group was older and had higher serum
creatinine levels than the other groups. There were no statistically significant intergroup differences in remission or
relapse, whereas serious infection developed more frequently in the high-dose (29 patients [43%]) than the low-
dose (13 patients [22%]) or medium-dose (10 patients [19%]) groups (p = 0.0007). Frequent VDI items at 12 months
included hypertension (19%), diabetes (13%), atrophy and weakness (13%), osteoporosis (8%), and cataracts (8%).
Logistic regression analysis revealed that GC dose at 12 months (odds ratio, 1.14; 95% confidence interval, 1.00–1.35)
was a predictor for diabetes.
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Conclusion: A reduced initial GC dose with rapid reduction might be required to ensure the safe treatment of
elderly AAV patients.
Keywords: ANCA-associated vasculitis, Chronic damage, Elderly patients, Glucocorticoids
Introduction
Treatment with high-dose glucocorticoid (GC) and
immunosuppressants has greatly improved the prognosis
of patients with antineutrophil cytoplasmic antibody
(ANCA)–associated vasculitis (AAV) [1, 2], but chronic
damage has become a major concern in such patients.
Because disease severity was reportedly related to
chronic damage [3], intensive immunosuppressive treat-
ment is required to induce the remission of AAV. On
the other hand, GC is a risk factor for chronic damage
as well as infectious complications [4, 5].
AAV often occurs in elderly populations, particularly
in Japan [6], and aging is a strong risk factor for death
and end-stage renal disease [7–10]. Due to the high inci-
dence of chronic conditions including diabetes mellitus,
osteoporosis, cataracts, and hypertension in elderly pop-
ulations with AAV [11], GC-related damage might be
more serious. Because many studies of AAV have ex-
cluded elderly patients, optimization of the initial GC
dose and tapering speed might be required to ensure
their safe treatment.
In this study, treatment-related damage was evaluated
in patients with elderly-onset AAV based on safety out-
come analysis using data from two nationwide prospect-
ive inception cohort studies.
Methods
Database
We used datasets from two cohort studies: RemIT-JAV
(observational cohort study of remission induction
therapy in Japanese patients with ANCA-associated
vasculitis [UMIN000001648]) and RemIT-JAV-RPGN
(observational cohort study of remission induction ther-
apy in Japanese patients with ANCA-associated
vasculitis and rapidly progressive glomerulonephritis
[UMIN000005136]). Consecutive patients with newly di-
agnosed AAV were enrolled in RemIT-JAV between
April 2009 and December 2010 from 22 tertiary care in-
stitutions or in RemIT-JAV-RPGN from April 2011 to
March 2014 from 53 tertiary care institutions. The cri-
teria for enrolment for both studies included the follow-
ing: (1) diagnosis of AAV by the site investigators, (2)
fulfillment of criteria for primary systemic vasculitis as
proposed by the European Medicines Agency algorithm
[12], and (3) starting immunosuppressive treatment
based on site investigator discretion [13, 14]. The exclu-
sion criteria were as follows: (1) age younger than 20
years, (2) serologic evidence of hepatitis B or C virus in-
fection, and (3) a history of malignancy. Baseline data
recorded for each patient included demographic infor-
mation, laboratory data, Birmingham Vasculitis Activity
Score (BVAS) 2003 [15], and disease severity. Disease
severity was subclassified as localized, early systemic,
generalized, or severe according to the European Vascu-
litis Study Group definition of disease severity types [16].
Patients with threatened vital organ function were classi-
fied as having generalized disease, while those with
organ failure were classified as having severe disease. De-
tailed definitions of disease severity were described pre-
viously [17]. Patients were evaluated at 3, 6, 12, 18, and
24months and at relapse, and the following data were
collected: vital status, BVAS 2003, laboratory data, treat-
ments, and adverse events. The Vasculitis Damage Index
(VDI) score was recorded at 6, 12, and 24months [18].
Patient selection and outcome measures
In the present study, patients with elderly-onset (≥ 75
years) AAV were enrolled. Patients for whom data about
the GC dose were lacking were excluded.
The primary outcome measure was 12-month
treatment-related VDI score. Treatment-related VDI was
defined as in the previous report as follows: osteoporosis,
diabetes, cataracts, atrophy and weakness, malignancy,
gonadal failure, marrow failure, chemical cystitis,
avascular necrosis, hypertension, angina/coronary artery
disease, alopecia, cerebrovascular accident, myocardial
infarction, and mouth ulcers [4]. Secondary outcome
measures included serious infections within 6months,
12-month total VDI score, remission, and relapse. Our
definition of serious infections was based on an Inter-
national Conference on Harmonization report [19].
Bacterial infections requiring intravenous antibiotic ad-
ministration and opportunistic infections were consid-
ered serious infections. The diagnosis of infection was
based on the attending physician’s clinical diagnosis
using a comprehensive evaluation of physical findings,
laboratory data, and imaging data. Remission was de-
fined as a BVAS score of 0 on 2 consecutive occasions at
least 1 month apart according to the European League
Against Rheumatism (EULAR) recommendations [16].
Relapse was defined as recurrent or new-onset clinical
signs and symptoms attributable to active vasculitis as
we previously reported [20].
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Statistical analysis
Clinical characteristics are presented as mean ± standard
deviation (SD). The patients were divided into three
groups according to initial GC dose: high-dose, prednis-
olone (PSL) ≥ 0.8 mg/kg/day; medium-dose, 0.6 ≤ PSL <
0.8 mg/kg/day; and low-dose, PSL < 0.6 mg/kg/day. Pa-
tient characteristics and outcomes were compared across
the three GC dose groups. Continuous variables were
compared using the Mann–Whitney U test, whereas cat-
egorical variables were compared between two groups
using the Fisher exact probability test. p values < 0.05
were considered significant. Statistical significance was
determined using Bonferroni correction, < 0.05/3, to ad-
just for multiple testing. To explore the factors related
to VDI items, multiple linear regression and logistic re-
gression analyses were performed. All statistical analyses
were performed using JMP 11.2.0 software (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Patient characteristics
Of 477 patients registered in the two cohort studies, 181
fulfilled the inclusion criteria. Among them, 2 were ex-
cluded because of a lack of data about the GC dose. For
the analysis of VDI score, 60 patients without a 12-
month score were excluded. Of those 60 excluded pa-
tients, 19 died by 12months. The mean age (SD) of the
179 enrolled patients was 80.0 (3.8) years, 111 (62%)
were female, and the baseline mean (SD) BVAS was 16.1
(6.6). Seven (4%) patients had eosinophilic granulomato-
sis with polyangiitis, 28 (16%) had granulomatosis with
polyangiitis, 113 (63%) had microscopic polyangiitis, and
31 (17%) were unclassifiable. Myeloperoxidase–antineu-
trophil cytoplasmic antibody (MPO-ANCA) results were
positive in 168 (94%) patients, while proteinase 3–ANCA
(PR3-ANCA) results were positive in 11 (6%) patients.
Concomitant cyclophosphamide (CY) was used in 54
(30%) patients, and the mean (SD) GC dose was 0.73
(0.25) mg/kg/day. Prophylaxis against Pneumocystis
pneumonia was administrated in 153 of 178 (86%) pa-
tients (there was no statistical difference compared to
patients aged < 75 years: 243 of 292 [83%], p = 0.43).
The patient characteristics of the three groups are
summarized in Table 1. The low-dose group had a sig-
nificantly higher mean age than the high-dose group.
There were no significant intergroup differences in sex,
disease classification, or disease severity. Mean BVAS
score did not differ significantly, while the high-dose
Table 1 Patient characteristics by initial GC dose group
Low-dose (n = 59) Medium-dose (n = 52) High-dose (n = 68)
Male/female 27/32 18/34 23/45
Age (years), mean ± SD (median)† 80.9 ± 3.9 (80) 79.9 ± 3.6 (80) 79.1 ± 3.6 (78)
Disease classification, n
EGPA 2 2 3
GPA 5 9 14
MPA 42 33 38
Unclassifiable 10 8 13
Disease severity, n (%)
Localized 1 3 3
Early systemic 12 14 18
Systemic 34 27 35
Severe 12 8 12
BVAS, mean ± SD 15.8 ± 6.3 17.3 ± 6.0 15.4 ± 7.2
MPO-ANCA–positive, n (%) 55 (93) 49 (94) 64 (94)
PR3-ANCA–positive, n (%) 0 2 (4) 3 (4)
Serum creatinine (mg/dL), mean ± SD† 3.11 ± 3.56 2.36 ± 2.15 1.59 ± 1.31
Interstitial lung disease, n (%) 29 (49) 24 (46) 29 (43)
Treatment
Initial daily dose of PSL (mg/kg/day), mean ± SD#, † 0.47 ± 0.10 0.69 ± 0.05 0.98 ± 0.18
Cyclophosphamide, n (%) 8 (13) 10 (19) 36 (53)
Comparisons among groups were made using the Mann–Whitney U test or Fisher’s exact probability test. Statistical significance was determined by using
Bonferroni correction (< 0.05/3). ANCA antineutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, EGPA eosinophilic granulomatosis with
polyangiitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase 3, PSL prednisolone, SD standard deviation
#Medium-dose vs. high-dose group
†Low-dose vs. high-dose group
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group exhibited a significantly lower mean serum cre-
atinine level than the low-dose group.
Mean (SD) daily PSL doses at initial treatment in the
low-, medium-, and high-dose groups were 0.47 (0.10),
0.69 (0.05), and 0.98 (0.18) mg/kg, respectively. The pro-
portion of concomitant CY use was significantly differ-
ent among groups: low-dose, 8 (13%); medium-dose, 10
(19%); and high-dose, 36 (53%); p < 0.0001.
Treatment effectiveness and safety
By 12 months, 151 (84%) patients achieved remission; of
those, 17 (11%) experienced a relapse. Mean (SD) total
VDI score at 12 months was 2.4 (1.8), while mean (SD)
treatment-related VDI score was 0.7 (1.0). The propor-
tions of patients with each VDI item at 12 months are
shown in Fig. 1. Frequent VDI items (> 5% of enrolled
patients) were as follows: hypertension (19%), diabetes
(13%), atrophy and weakness (13%), osteoporosis (8%),
and cataracts (8%). Serious infections within 6 months
developed in 52 (29%) patients.
There were no statistically significant intergroup dif-
ferences in remission or relapse by 12 months: remis-
sion—50 (85%) of 59 patients in low-dose, 41 (79%) of
52 in medium-dose, and 60 (88%) of 68 in high-dose, re-
spectively, p = 0.38; relapse—5 (10%) of 50 in low-dose, 5
(12%) of 41 in medium-dose, and 7 (12%) of 60 in high-
dose, respectively, p = 0.93. Even limited in patients with
severe form, remission and relapse were not different
statistically (remission: 66% in low-dose, 63% in
medium-dose, and 67% in high-dose, respectively, p =
0.98; relapse: 0%, 20%, and 13%, respectively, p = 0.46).
Serious infections developed more frequently in the
high-dose (n = 29 [43%]) than in the low-dose (n = 13
[22%]) or medium-dose (n = 10 [19%]) groups (p =
0.0007). Same trends were found in each dataset (Re-
mIT-JAV group: 45% in high-dose, 13% in medium-
dose, and 15% in low-dose, respectively, p = 0.04;
RemIT-JAV-RPGN group: 41% in high-dose, 22% in
medium-dose, and 24% in low-dose, respectively, p =
0.10).
Vasculitis Damage Index
Mean (SD) VDI scores of all patients in the RemIT-JAV
and RemIT-JAV-RPGN groups were 1.7 (1.7) and 2.1
(1.6) at 6 months, and 2.0 (1.7) and 2.5 (1.8) at 12
months, respectively.
Of 121 patients with VDI scores at 12 months, total
and treatment-related VDI scores at 12 months showed
no statistically significant intergroup differences (total
VDI score: low-dose, 2.65 ± 1.99; medium-dose, 2.40 ±
1.67; and high-dose, 2.25 ± 1.70, p = 0.57; treatment-
related VDI score: low-dose, 0.91 ± 1.18; medium-dose,
0.45 ± 0.71; and high-dose, 0.77 ± 1.04, p = 0.14).
For the determination of variables associated with total
and treatment-related VDI scores at 12 months, a mul-
tiple linear regression analysis was performed of the fol-
lowing candidate variables: sex, age, initial GC dose,
initial CY usage, and initial serum creatinine level. No
Fig. 1 Frequency of treatment-related VDI items at 12months. VDI, Vasculitis Damage Index
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statistically significant variables were identified (Supple-
mentary Table 1).
Next, we explored variables related to 5 frequent
treatment-related VDI items at 12 months using logistic
regression analysis including the same candidate vari-
ables. Hypertension, atrophy and weakness, osteoporosis,
and cataracts were eliminated (Supplementary Table 2),
while CY usage was identified as an independent pre-
dictor for a less frequent development of diabetes
(Table 2, model 1).
Because mean (SD) GC dose at 12 months was lower
in patients with concomitant CY than in those without it
(6.8 [3.5] vs. 9.5 [6.9] mg/day, p = 0.016), we performed a
multiple linear regression analysis including GC dose at
12 months instead of concomitant CY usage; GC dose at
12 months was also identified as an independent pre-
dictor for diabetes (Table 2, model 2).
Discussion
This is the first report to evaluate damage in elderly pa-
tients with AAV. The low-dose initial GC group was
older and had more severe renal impairment but less
frequent concomitant CY use. The high-dose group
more frequently developed serious infections. Total and
treatment-related VDI scores did not differ significantly
among the initial GC dose groups. GC dose at 12
months was an independent predictor for diabetes.
Our findings suggest that initial GC dose perhaps is
reduced during treatment in elderly patients with AAV.
Serious infections developed more frequently in the
high-dose group, but remission, relapse, and VDI score
were comparable to those of the other groups. Although
CY dose was recommended to be reduced according to
age and renal function with concern about adverse drug
reactions in the EULAR recommendation for the
treatment of AAV [21], the initial dose adjustment of
GC was not stated, and PSL 1mg/kg/day has tradition-
ally been initiated since the 1970s [22]. The PEXIVAS
trial reported that a reduced-dose GC regimen (initial
dose, ~ 0.5 mg/kg/day) was non-inferior to the standard
regimen (initial dose, ~ 1 mg/kg/day) with respect to
death or end-stage renal failure in patients with severe
AAV [23]. Initial GC dose and age were reportedly re-
lated to serious infection in the immunosuppressive
treatment of rheumatic diseases [24–26]. Our previous
study also showed that PSL > 0.8 mg/kg/day was a risk
factor for severe infection in patients with AAV [5].
Therefore, the reduction of the initial GC dose could
lead to improved safety outcomes in elderly patients.
Diabetes, atrophy and weakness, osteoporosis, and cat-
aracts were emphasized as chronic damage in elderly
AAV patients. Although the order of the frequency of
treatment-related VDI items was comparable to those of
the previous report for VDI for AAV patients of all ages,
diabetes (13% in present study vs. 8% in the previous
study), atrophy and weakness (13% vs. 6%), osteoporosis
(8% vs. 4%), and cataracts (8% vs. 3%) were more fre-
quent in the present study [27]. These items are also
well-known concerns in general elderly patients, and our
result indicates that AAV treatment accelerates this
damage in elderly AAV patients.
A delay in the GC reduction without concomitant CY
usage and renal impairment might lead to the develop-
ment of diabetes. Concomitant CY usage was deter-
mined as a protective predictor for diabetes by analysis
of initial treatment with patient characteristics. Our re-
cent study also demonstrated a GC sparing effect of con-
comitant CY in AAV patients, as the GC dose at 12
months was lower in patients with concomitant CY than
those without CY [28]. Even on multivariate analysis
with the model including GC dose at 12 months instead
of concomitant CY usage, GC dose at 12 months
remained a statistical predictor for diabetes. Because the
achievement of PSL 5–7.5 mg/day by 5 months is recom-
mended in the EULAR guidelines, an earlier reduction
of GC dose might be attempted in elderly AAV patients
with renal impairment [21].
There are some limitations to this study. First, the ma-
jority of our patients were MPO-ANCA–positive. There
are several differences in characteristics between patients
with MPO-ANCA and those with PR3-ANCA [29, 30],
and our results might not be applicable to the treatment
of elderly patients with PR3-ANCA. Second, the treat-
ment strategy was decided by each attending physician,
so frail patients might have been treated conservatively,
leading to underestimation of the outcomes. Neverthe-
less, patients with higher GC doses at 12 months had
diabetes more frequently, supporting the relevance of a
sufficient and early GC dose reduction in elderly
Table 2 Risk factors for the development of diabetes at 12
months
Odds ratio (95% CI) p value
Model 1
Age, years 1.06 (0.93–1.24) 0.36
Female sex 0.73 (0.24–2.01) 0.55
Serum creatinine, mg/dL 0.83 (0.66–0.99) 0.040
Initial PSL dose, mg/kg/day 3.32 (0.29–41.66) 0.34
Concomitant cyclophosphamide use 0.29 (0.09–0.87) 0.027
Model 2
Age, years 1.08 (0.94–1.26) 0.28
Female sex 0.76 (0.25–2.09) 0.60
Serum creatinine, mg/dL 0.86 (0.70–1.02) 0.09
Initial PSL dose, mg/kg/day 1.26 (0.13–14.65) 0.85
PSL dose at 12 months, mg/day 1.14 (1.00–1.35) 0.045
CI confidential interval, PSL prednisolone
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patients. Third, we could not validate our exploratory re-
sults in another dataset because of insufficient sample
size, so further validation study is required.
Conclusion
Rapidly reducing the initial GC dose to PSL < 0.8 mg/kg/
day perhaps is required to ensure the safe treatment of
elderly patients with AAV.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02341-6.
Additional file 1: Table S1. Risk factors for total and treatment-related
VDI. Table S2. Risk factors for hypertension, atrophy and weakness, cata-
ract, and osteoporosis.
Abbreviations
AAV: Antineutrophil cytoplasmic antibody–associated vasculitis;
ANCA: Antineutrophil cytoplasmic antibody; BVAS: Birmingham Vasculitis
Activity Score; CY: Cyclophosphamide; EULAR: European League Against
Rheumatism; GC: Glucocorticoid; MPO-ANCA: Myeloperoxidase–
antineutrophil cytoplasmic antibody; PR3-ANCA: Proteinase 3–antineutrophil
cytoplasmic antibody; PSL: Prednisolone; RemIT-JAV: Observational cohort
study of remission induction therapy in Japanese patients with
antineutrophil cytoplasmic antibody-associated vasculitis; RemIT-JAV-
RPGN: Observational cohort study of remission induction therapy in
Japanese patients with antineutrophil cytoplasmic antibody-associated vascu-
litis and rapidly progressive glomerulonephritis; SD: Standard deviation;
VDI: Vasculitis Damage Index
Acknowledgements
The authors thank all the medical staff members in our department.
Japan Research Committee of the Ministry of Health, Labour, and Welfare for
Intractable Vasculitis (JPVAS) and Research Committee of Intractable Renal
Disease of the Ministry of Health, Labour, and Welfare of Japan—in addition
to the authors, the following investigators and institutions participated in
this study: Department of Nephrology, Faculty of Medicine, University of
Tsukuba (Joichi Usui); Department of Rheumatology, Endocrinology and
Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido
University (Tatsuya Atsumi); Department of Medicine and Rheumatology,
Tokyo Metropolitan Geriatric Hospital (Takahiko Sugihara); Department of
Nephrology, Internal Medicine, Nagoya University Graduate School of
Medicine (Seiichi Matsuo); Department of Human Resource Development of
Dialysis Therapy for Kidney Disease, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences (Hitoshi Sugiyama); Faculty
of Health Sciences, Hokkaido University (Akihiro Ishizu); Department of the
Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto
University (Takao Fujii); Department of Pathology, Keio University School of
Medicine (Yasunori Okada); Department of Respiratory Medicine, Toho
University Omori Medical Center (Sakae Homma); Department of
Nephrology, Internal Medicine, Nagoya University Graduate School of
Medicine (Naotake Tsuboi); Department of Clinical Pathology and
Immunology, Kobe University Graduate School of Medicine (Shunichi
Kumagai); Department of Nephrology and Dialysis, Kitano Hospital, Tazuke
Kofukai Medical Research Institute (Eri Muso); Department of Rheumatology,
Shimane University Faculty of Medicine (Yohko Murakawa); Division of
Rheumatology, Department of Medical Oncology and Immunology, Nagoya
City University Graduate School of Medical Science (Shogo Banno);
Department of Hematology, Clinical Immunology and Infectious Diseases,
Ehime University Graduate School of Medicine (Hitoshi Hasegawa); Division
of Nephrology, Department of Internal Medicine, Jichi Medical University
(Wako Yumura); Department of Cardiovascular Medicine, Kyoto Prefectural
University School of Medicine (Hiroaki Matsubara); Division of Nephrology,
Tokyo Medical University Hachioji Medical Center (Masaharu Yoshida);
Department of Dermatology, Kitasato University School of Medicine (Kensei
Katsuoka); Division of Immunology and Rheumatology, Department of
Internal Medicine 3, Hamamatsu University School of Medicine (Noriyoshi
Ogawa); Department of Hematology, Oncology, Nephrology, and
Rheumatology, Akita University Graduate School of Medicine (Atsushi
Komatsuda); Department of Rheumatology, Niigata Rheumatic Center
(Satoshi Ito); Department of Immunology and Rheumatology, Division of
Advanced Preventive Medical Sciences, Nagasaki University Graduate School
of Biomedical Sciences (Atsushi Kawakami); Department of Nephrology,
Iwate Prefectural Central Hospital (Izaya Nakaya); Division of Nephrology and
Rheumatology, Department of Internal Medicine, Fukuoka University School
of Medicine (Takao Saito); Shimane University, Faculty of Medicine, Division
of Nephrology (Takafumi Ito); Department of Hemodialysis and Apheresis,
Yokohama City University Medical Center (Nobuhito Hirawa); Center for
Rheumatology, Okayama Saiseikai General Hospital (Masahiro Yamamura);
Department of Medical Technology, School of Health Sciences, Faculty of
Medicine, Niigata University (Masaaki Nakano); Department of Medicine,
Kidney Center, Tokyo Women’s Medical University (Kosaku Nitta); Division of
Nephrology and Hypertension, Kashiwa Hospital, Jikei University (Makoto
Ogura); Department of Respiratory Medicine, Allergy and Clinical
Immunology, Nagoya City University Graduate School of Medical Sciences
(Taio Naniwa); Division of Rheumatology and Allergology, Department of
Internal Medicine, St. Marianna University School of Medicine (Shoichi Ozaki);
Department of Nephrology and Endocrinology, Graduate School of
Medicine, The University of Tokyo (Junichi Hirahashi); Division of Kidney and
Hypertension, Department of Internal Medicine, Jikei University School of
Medicine (Tatsuo Hosoya); Department of Nephrology and Laboratory
Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and
Health Sciences, Kanazawa University (Takashi Wada); Division of Nephrology,
Department of Internal Medicine, Juntendo University Faculty of Medicine
(Satoshi Horikoshi); Institute of Rheumatology, Tokyo Women’s Medical
University (Yasushi Kawaguchi); Division of Clinical Immunology, Graduate
School of Comprehensive Human Sciences, University of Tsukuba (Taichi
Hayashi); Department of Nephrology, Hypertension, Diabetology,
Endocrinology and Metabolic, Fukushima Medical University (Tsuyoshi
Watanabe); Department of Nephrology, Japanese Red Cross Nagoya Daini
Hospital (Daijo Inaguma); Department of Integrated Therapy for Chronic
Kidney Disease, Kyushu University (Kazuhiko Tsuruya); Niigata Prefectural
Shibata Hospital (Noriyuki Homma); Division of Rheumatology, Department
of Internal Medicine, Keio University School of Medicine (Tsutomu Takeuchi);
Division of Cardiology, Nephrology, Pulmonology and Neurology,
Department of Internal Medicine, Asahikawa Medical University (Naoki
Nakagawa); Kurobe City Hospital (Shinichi Takeda); National Fukuoka Higashi
Medical Center (Ritsuko Katafuchi); Division of Nephrology, Department of
Medicine, Faculty of Medical Sciences, University of Fukui (Masayuki Iwano);
and Tokyo Medical University Ibaraki Medical Center (Masaki Kobayashi).
Authors’ contributions
KS and KO were responsible for the conception and design, analysis, and
manuscript writing. YA, KH, MM, HW, and YM were responsible for the data
collection and critical revision. SF, YT, KY, SB, HD, and KA were responsible
for the data collection and interpretation. MH, YA, and HM were responsible
for the data collection, interpretation, and critical revision. YA was
responsible for the conception and design, data collection and analysis, and
critical revision. HM was responsible for the data analysis, interpretation, and
critical revision. The authors read and approved the final manuscript.
Funding
This work was supported by grants from the Ministry of Health, Labour, and
Welfare, Japan (nannti-ippann-004 and nannti-ippann-018), and the Japan
Agency for Medical Research and Development (JP17ek0109104,
JP17ek0109121, and JP18ek0109360).
Availability of data and materials
The dataset analyzed in this paper is available from the corresponding
author on reasonable request.
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki
and the ethical guidelines for epidemiological research in Japan. This study
was approved by the Ethics Committee of Okayama University Hospital and
Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Sada et al. Arthritis Research & Therapy          (2020) 22:236 Page 6 of 8
(approval number, Ken1904-023). Informed consent and permission to pub-
lish their data were obtained from all participants.
Consent for publication
No individual person’s data were presented in any form in this study, and
therefore, no consent to publish is required.
Competing interests
KS received speaker’s fee from Astra Zeneca K.K. KA received speaker’s fee
from Chugai Pharmaceutical Co. MH has received unrestricted research
grants from AbbVie Japan GK; Ayumi Pharmaceutical Co.; Bristol Myers
Squibb Co., Ltd.; Eisai Co., Ltd.; Nippon Kayaku Co., Ltd.; Mitsubishi Tanabe
Pharma Co.; and Teijin Pharma Ltd. MH has received speaker’s fee from
Boehringer-Ingelheim; Kissei Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; and
Chugai Pharmaceutical Co., Ltd. MH is a consultant for AbbVie; Boehringer-
Ingelheim; Kissei Pharmaceutical Co., Ltd.; and Teijin Pharma. HM is a consult-
ant for AbbVie, Boehringer-Ingelheim, and Teijin.
Author details
1Department of Clinical Epidemiology, Kochi Medical School, Kochi
University, Kohasu, Oko-cho, Nankoku 783-8505, Japan. 2Department of
Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama
University Graduate School of Medicine, Dentistry, and Pharmaceutical
Sciences, Okayama, Japan. 3Department of Hemovascular Medicine and
Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
4Department of Internal Medicine and Rheumatology, Juntendo University
School of Medicine, Tokyo, Japan. 5Department of Nephrology, Faculty of
Medicine, University of Tsukuba, Ibaraki, Japan. 6Department of Nephrology
and Rheumatology, Aichi Medical University, Nagakute, Japan. 7Division of
Hematology, Rheumatology and Respiratory Medicine, Department of
Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
8Department of Rheumatology and Clinical Immunology, Saitama Medical
Center, Saitama Medical University, Kawagoe, Japan. 9Department of
Rheumatology, Tokyo Women’s Medical University School of Medicine,
Tokyo, Japan. 10Department of Nephrology and Rheumatology, Kyorin
University School of Medicine, Tokyo, Japan. 11Kichijoji Asahi Hospital, Tokyo,
Japan. 12Okayama University, Okayama, Japan.
Received: 9 July 2020 Accepted: 2 October 2020
References
1. Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, Fertmann R,
Reinhold-Keller E. Improved outcome in 445 patients with Wegener’s
granulomatosis in a German vasculitis center over four decades. Arthritis
Rheum. 2011;63(1):257–66.
2. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda VP, Cohen
Tervaert JW. Improved outcome in anti-neutrophil cytoplasmic antibody
(ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol
Dial Transplant. 2013;28(2):373–9.
3. Sreih AG, Mandhadi R, Aldaghlawi F, Khan A, Irshad V, Finn K, Block JA.
ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity.
Clin Rheumatol. 2015;34(5):943–8.
4. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, Jayne D,
Mahr A, Westman K, Luqmani R. Glucocorticoid treatment and damage in
the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term
data from the European Vasculitis Study Group trials. Rheumatology
(Oxford). 2015;54(3):471–81.
5. Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H,
Amano K, Ito S, Homma S, Kumagai S, et al. Clinical characteristics of and
risk factors for serious infection in Japanese patients within six months of
remission induction therapy for antineutrophil cytoplasmic antibody-
associated vasculitis registered in a nationwide, prospective, inception
cohort study. Mod Rheumatol. 2017;27(4):646–51.
6. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, Hashimoto
H, Nunoi H. Comparison of the epidemiology of anti-neutrophil cytoplasmic
antibody-associated vasculitis between Japan and the U.K. Rheumatology
(Oxford). 2011;50(10):1916–20.
7. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the
twentieth century--a disease of older patients. Rheumatology (Oxford). 2005;
44(4):495–501.
8. Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibody-
associated vasculitis in older patients. Medicine (Baltimore). 2008;87(4):203–9.
9. Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B,
D'Agati VD, Markowitz GS. ANCA-associated glomerulonephritis in the very
elderly. Kidney Int. 2011;79(7):757–64.
10. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C,
Jayne D, Harper L, European Vasculitis Study G. Early mortality in systemic
vasculitis: relative contribution of adverse events and active vasculitis. Ann
Rheum Dis. 2010;69(6):1036–43.
11. Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, Selga
D, Chocova Z, Westman K, Eriksson P, et al. Outcome and treatment of
elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol.
2015;10(7):1128–35.
12. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A,
Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a
consensus methodology for the classification of the ANCA-associated
vasculitides and polyarteritis nodosa for epidemiological studies. Ann
Rheum Dis. 2007;66(2):222–7.
13. Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S,
Yamada H, Wada T, Hirahashi J, et al. Classification and characteristics of
Japanese patients with antineutrophil cytoplasmic antibody-associated
vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res
Ther. 2014;16(2):R101.
14. Sada KE, Yamamura M, Harigai M, Fujii T, Arimura Y, Makino H. Issues
associated with the Ministry of Health, Labour and Welfare diagnostic
criteria for antineutrophil cytoplasmic antibody-associated vasculitides:
reclassification of patients in the prospective cohort study of Remission
Induction Therapy in Japanese patients with ANCA-associated vasculitides
according to the MHLW criteria. Mod Rheumatol. 2015;25(4):657–9.
15. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman
K, Luqmani R. Development of comprehensive disease assessment in
systemic vasculitis. Ann Rheum Dis. 2007;66(3):283–92.
16. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin
L, Jayne D, Mahr A, Merkel PA, Raspe H, et al. EULAR recommendations for
conducting clinical studies and/or clinical trials in systemic vasculitis: focus
on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis.
2007;66(5):605–17.
17. Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y,
Banno S, Sugihara T, Kobayashi M, et al. Comparison of severity classification
in Japanese patients with antineutrophil cytoplasmic antibody-associated
vasculitis in a nationwide, prospective, inception cohort study. Mod
Rheumatol. 2016;26(5):730–7.
18. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D.
Development and initial validation of the Vasculitis Damage Index for the
standardized clinical assessment of damage in the systemic vasculitides.
Arthritis Rheum. 1997;40(2):371–80.
19. Vijayananthan A, Nawawi O. The importance of Good Clinical Practice
guidelines and its role in clinical trials. Biomed Imaging Interv J. 2008;4(1):e5.
20. Hara A, Wada T, Sada KE, Amano K, Dobashi H, Harigai M, Takasaki Y,
Yamada H, Hasegawa H, Hayashi T, et al. Risk factors for relapse of
antineutrophil cytoplasmic antibody-associated vasculitis in Japan: a
nationwide, prospective cohort study. J Rheumatol. 2018;45(4):521–8.
21. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B,
Holle JU, Laudien M, Little MA, et al. EULAR/ERA-EDTA recommendations for
the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):
1583–94.
22. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener’s
granulomatosis. N Engl J Med. 1971;284(17):938–42.
23. Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, Hawley CM,
Khalidi N, Flossmann O, Wald R, et al. Plasma exchange and glucocorticoids
in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31.
24. Wilson JC, Sarsour K, Gale S, Petho-Schramm A, Jick SS, Meier CR. Incidence
and risk of glucocorticoid-associated adverse effects in patients with
rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(4):498–511.
25. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, Mouthon
L, Guillevin L. Risk factors and prognostic influence of infection in a single
cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis.
2001;60(12):1141–4.
26. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide
MV, Aguirre C. Predictors of major infections in systemic lupus
erythematosus. Arthritis Res Ther. 2009;11(4):R109.
Sada et al. Arthritis Research & Therapy          (2020) 22:236 Page 7 of 8
27. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, Jayne D,
Mahr A, Westman K, Luqmani R. Damage in the anca-associated
vasculitides: long-term data from the European vasculitis study group
(EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–84.
28. Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Fujimoto S,
Dobashi H, Yuzawa Y, Yamagata K, Muso E, et al. Rationale of concomitant
cyclophosphamide for remission-induction in patients with antineutrophil
cytoplasmic antibody-associated vasculitis: a propensity score-matched
analysis of two nationwide prospective cohort studies. Mod Rheumatol.
2020:1–9. https://doi.org/10.1080/14397595.2019.1707997.
29. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH,
Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic
autoantibody vasculitides: the role of antineutrophil cytoplasmic
autoantibody specificity for myeloperoxidase or proteinase 3 in disease
recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–62.
30. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B,
Brenchley P, Bruchfeld A, Chaudhry AN, et al. Genetically distinct subsets
within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sada et al. Arthritis Research & Therapy          (2020) 22:236 Page 8 of 8
